je.st
news
With $450M sale, Alnylam has more cash than any pre-commercial biotech
2015-01-20 19:26:36| Biotech - Topix.net
Thanks to a massive infusion of cash a year ago from neighboring Genzyme , Alnylam Pharmaceuticals already has more cash and other assets that can be easily converted into cash than any other biotech with no products on the market in the U.S. With a $450 million offering announced today, it will soon have about 50 percent more. Alnylam 's shares were down only slightly today - about 3 percent to $97.44 as of noon - after announcing the secondary stock offering, easily among the biggest in biotech in the past several years.
Tags: sale
cash
biotech
450m
Category:Biotechnology and Pharmaceuticals